Figure 1.
Key outcomes for the BUILD-2 study of bosentan versus placebo in SSc-ILD. BUILD, Bosentan
in Interstitial Lung Disease in Systemic Sclerosis; DLCO, carbon dioxide diffusing
capacity; EOS, end of study; FVC, forced vital capacity; ILD, interstitial lung disease;
6 MWD, 6 min walk distance; Rx, treatment; SSc, systemic sclerosis.
Matucci-Cerinic et al. Arthritis Research & Therapy 2007 9(Suppl 2):S7 doi:10.1186/ar2191 |
